TL;DR
This study used a network meta-analysis to compare seven drug therapies for cerebral infarction (CI). Aspirin plus dipyridamole emerged as the most effective treatment, demonstrating the highest likelihood of being the optimal choice for reducing mortality, intracranial hemorrhage, and adverse events.
What Problem Does This Paper Address?
Cerebral infarction (CI), a type of ischemic stroke, is a major cause of disability and mortality worldwide. While various drug therapies exist for its treatment, there's a lack of clear consensus on which is most effective. This paper aims to standardize clinical practice by systematically comparing the efficacy and safety of seven common drug therapies for CI, including aspirin, aspirin plus dipyridamole, aspirin plus clopidogrel, aspirin plus warfarin, cilostazol, warfarin, and ticlopidine.
Methods
The researchers conducted a network meta-analysis, a statistical technique that allows for the comparison of multiple treatments simultaneously, even when direct head-to-head comparisons are limited. They searched major databases for relevant randomized controlled trials (RCTs). The analysis pooled data to estimate odds ratios (ORs) for various outcomes. A key component of their analysis was the calculation of Surface Under the Cumulative Ranking Curves (SUCRA) values. SUCRA provides a probabilistic ranking of treatments, indicating the likelihood of each treatment being the best, second best, and so on, for a given outcome. This approach helps to overcome the limitations of traditional pairwise meta-analyses by allowing for indirect comparisons between treatments.
Datasets
The study utilized data from 13 eligible randomized controlled trials (RCTs) involving a total of 16,771 participants. These trials were published between 2001 and 2017 and included patients from European, American, and Asian populations. No new datasets were introduced by this paper.
Key Insights and Ideas
- Aspirin + Dipyridamole Shines: The combination of aspirin and dipyridamole consistently ranked highest across multiple critical outcomes, suggesting a synergistic effect that enhances its therapeutic value.
- SUCRA as a Powerful Ranking Tool: The use of SUCRA values provided a clear and probabilistic way to rank treatments, moving beyond simple ORs to offer a more nuanced understanding of treatment effectiveness.
- Aspirin + Clopidogrel Underperforms: Counterintuitively, the combination of aspirin and clopidogrel, while a common therapy, was found to be the least effective among the tested regimens for CI.
- No Significant Differences for Some Outcomes: While mortality and adverse events showed clear winners, the study found no significant differences in efficacy among the seven drugs for intracranial hemorrhage and stroke recurrence rates.
Key Results
- Mortality: Aspirin plus dipyridamole demonstrated the highest SUCRA value (80.67%), indicating it's the most likely to be the best treatment for reducing mortality in CI patients.
- Intracranial Hemorrhage (ICH): Aspirin plus dipyridamole also had the highest SUCRA for ICH (76.6%).
- Adverse Event (AE) Rate: Aspirin plus dipyridamole was again ranked highest for AE rate (90.2%), suggesting it's the safest option.
- Stroke Recurrence: Cilostazol ranked highest for stroke recurrence, though the differences among treatments for this outcome were not as pronounced.
- Direct Comparison: Aspirin plus dipyridamole was found to have a lower mortality rate compared to aspirin plus clopidogrel (OR=0.46, 95% CI=0.18–0.99).
- Least Desired Treatment: Aspirin plus clopidogrel was the least frequently chosen treatment in the included studies, aligning with its poorer performance in the analysis.
Limitations and Future Work
The authors acknowledge several limitations:
- Geographic Scope: The study's findings are based on data from European, American, and Asian populations, and may not be generalizable to other ethnic groups.
- Sample Size: The meta-analysis included 13 studies, which the authors consider a relatively small number, potentially limiting the statistical power for some comparisons.
Future work could involve expanding the analysis to include a larger number of studies and a broader range of patient demographics. The authors suggest their findings can serve as an updated supplement to clinical guidelines and help predict future research needs.
Summary updated